<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Antibacterials: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int127-antibacterials.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int127-antibacterials.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="bnf_int127-antibacterials.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int125-propafenone.htm" title="Previous: Propafenone">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1069-tigecycline.htm" title="Next: Tigecycline">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Antibacterials</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p><strong>Antibacterials</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1058-typhoid-vaccine-oral.htm">Typhoid Vaccine (oral)</a></td><td><p><span></span> <span>antibacterials</span> <span>inactivate</span> <span>oral typhoid vaccine</span><span>—see under Typhoid vaccines, <a title="monograph-family: Typhoid vaccines" href="PHP8409-typhoid-vaccines.htm">section 14.4</a></span></p></td><td></td></tr></tbody></table><p><strong>Tigecycline</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>tigecycline</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr></tbody></table><p><strong>Daptomycin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>daptomycin</span> <span>given with</span> <span>ciclosporin</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int594-fibrates.htm">Fibrates</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>daptomycin</span> <span>given with</span> <span>fibrates</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int600-statins.htm">Statins</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>daptomycin</span> <span>given with</span> <span>statins</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr></tbody></table><p><strong>Co-trimoxazole</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><div class="cG"><p><strong>Note:</strong> Co-trimoxazole interactions as for trimethoprim and sulfamethoxazole</p></div><p><strong>Telithromycin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>telithromycin</span> <span>given with</span> <span>amiodarone</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>telithromycin</span> <span>given with</span> <span>tricyclics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>aprepitant</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>telithromycin</span> <span>advises avoid concomitant use with</span> <span>atazanavir</span> <span>in severe renal and hepatic impairment</span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>telithromycin</span> <span>given with</span> <span>atorvastatin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1235-axitinib.htm">Axitinib</a></td><td><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>axitinib</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span><span>telithromycin</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>possibly inhibits metabolism of</span> <span>calcium-channel blockers</span> <span>(increased risk of side-effects)</span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>telithromycin</span> <span>reduced by</span> <span>carbamazepine</span> <span>(avoid during and for 2 weeks after <span>carbamazepine</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int374-chlorpromazine.htm">Chlorpromazine</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>telithromycin</span> <span>given with</span> <span>chlorpromazine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int233-citalopram.htm">Citalopram</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>telithromycin</span> <span>given with</span> <span>citalopram</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span></p></td><td></td></tr><tr><td><a href="bnf_int1240-crizotinib.htm">Crizotinib</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>crizotinib</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>telithromycin</span> <span>given with</span> <span>disopyramide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>telithromycin</span> <span>given with</span> <span>dronedarone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>increases plasma concentration of</span> <span>eplerenone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span><span>telithromycin</span> <span>given with</span> <span>ergotamine and methysergide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of <span>fesoterodine</span> advises dose reduction when </span><span>telithromycin</span> <span>given with</span> <span>fesoterodine</span><span>—consult <span>fesoterodine</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>telithromycin</span> <span>advises avoid concomitant use with</span> <span>fosamprenavir</span> <span>in severe renal and hepatic impairment</span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>telithromycin</span> <span>advises avoid concomitant use with</span> <span>indinavir</span> <span>in severe renal and hepatic impairment</span></p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>ivabradine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>manufacturer of </span><span>telithromycin</span> <span>advises avoid concomitant use with</span> <span>ketoconazole</span> <span>in severe renal and hepatic impairment</span></p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span><span>telithromycin</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>telithromycin</span> <span>advises avoid concomitant use with</span> <span>lopinavir</span> <span>in severe renal and hepatic impairment</span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>maraviroc</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>telithromycin</span> <span>given with</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>inhibits metabolism of</span> <span>midazolam</span> <span>(increased plasma concentration  with increased sedation)</span></p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>telithromycin</span> <span>given with</span> <span>moxifloxacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td class="cAI"><p><span>avoidance of </span><span>telithromycin</span> <span>advised by manufacturer of</span> <span>nilotinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int901-oxycodone.htm">Oxycodone</a></td><td><p><span></span> <span>telithromycin</span> <span>inhibits the metabolism of</span> <span>oxycodone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span><span>telithromycin</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>telithromycin</span> <span>given with parenteral</span> <span>pentamidine isetionate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>plasma concentration of </span><span>telithromycin</span> <span>reduced by</span> <span>phenobarbital</span> <span>(avoid during and for 2 weeks after <span>phenobarbital</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>telithromycin</span> <span>reduced by</span> <span>phenytoin</span> <span>(avoid during and for 2 weeks after <span>phenytoin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>telithromycin</span> <span>given with</span> <span>pimozide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int604-pravastatin.htm">Pravastatin</a></td><td><p><span>possible increased risk of myopathy when </span><span>telithromycin</span> <span>given with</span> <span>pravastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>telithromycin</span> <span>reduced by</span> <span>rifampicin</span> <span>(avoid during and for 2 weeks after <span>rifampicin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>telithromycin</span> <span>advises avoid concomitant use with</span> <span>ritonavir</span> <span>in severe renal and hepatic impairment</span></p></td><td></td></tr><tr><td><a href="bnf_int1231-ruxolitinib.htm">Ruxolitinib</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>telithromycin</span> <span>given with</span> <span>ruxolitinib</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>telithromycin</span> <span>advises avoid concomitant use with</span> <span>saquinavir</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>sildenafil</span><span>—reduce initial dose of <span>sildenafil</span></span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>telithromycin</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>increases plasma concentration of</span> <span>sirolimus</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>telithromycin</span> <span>reduced by</span> <span>St John's wort</span> <span>(avoid during and for 2 weeks after <span>St John's wort</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>telithromycin</span> <span>possibly increases plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of both drugs possibly increased when </span><span>telithromycin</span> <span>given with</span> <span>telaprevir</span> <span>(increased risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>manufacturer of </span><span>telithromycin</span> <span>advises avoid concomitant use with</span> <span>tipranavir</span> <span>in severe renal and hepatic impairment</span></p></td><td></td></tr></tbody></table><p><strong>Aminoglycosides</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>aminoglycosides</span> <span>given with</span> <span>amphotericin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int458-bisphosphonates.htm">Bisphosphonates</a></td><td><p><span>increased risk of hypocalcaemia when </span><span>aminoglycosides</span> <span>given with</span> <span>bisphosphonates</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int137-capreomycin.htm">Capreomycin</a></td><td><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>aminoglycosides</span> <span>given with</span> <span>capreomycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int141-cephalosporins.htm">Cephalosporins</a></td><td><p><span>possible increased risk of nephrotoxicity when </span><span>aminoglycosides</span> <span>given with</span> <span>cephalosporins</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span><span>aminoglycosides</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int190-colistimethate-sodium.htm">Colistimethate Sodium</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>aminoglycosides</span> <span>given with</span> <span>colistimethate sodium</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td class="cAI"><p><span>increased risk of otoxicity when </span><span>aminoglycosides</span> <span>given with</span> <span>loop diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int620-muscle-relaxants-non-depolarising.htm">Muscle Relaxants, non-depolarising</a></td><td class="cAI"><p><span></span> <span>aminoglycosides</span> <span>enhance effects of</span> <span>non-depolarising muscle relaxants</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int647-neostigmine.htm">Neostigmine</a></td><td class="cAI"><p><span></span> <span>aminoglycosides</span> <span>antagonise effects of</span> <span>neostigmine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int512-platinum-compounds.htm">Platinum Compounds</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity and possibly of ototoxicity when </span><span>aminoglycosides</span> <span>given with</span> <span>platinum compounds</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int189-polymyxins.htm">Polymyxins</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>aminoglycosides</span> <span>given with</span> <span>polymyxins</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int648-pyridostigmine.htm">Pyridostigmine</a></td><td class="cAI"><p><span></span> <span>aminoglycosides</span> <span>antagonise effects of</span> <span>pyridostigmine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td class="cAI"><p><span></span> <span>aminoglycosides</span> <span>enhance effects of</span> <span>suxamethonium</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span><span>aminoglycosides</span> <span>given with</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int218-vancomycin.htm">Vancomycin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>aminoglycosides</span> <span>given with</span> <span>vancomycin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Amikacin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int70-indometacin.htm">Indometacin</a></td><td><p><span>plasma concentration of </span><span>amikacin</span> <span>in neonates possibly increased by</span> <span>indometacin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Framycetin</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Gentamicin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1012-agalsidase-alfa-and-beta.htm">Agalsidase Alfa and Beta</a></td><td><p><span></span> <span>gentamicin</span> <span>possibly inhibits effects of</span> <span>agalsidase alfa and beta</span> <span>(manufacturers of <span>agalsidase alfa and beta</span> advise avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>gentamicin</span> <span>possibly increases plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int70-indometacin.htm">Indometacin</a></td><td><p><span>plasma concentration of </span><span>gentamicin</span> <span>in neonates possibly increased by</span> <span>indometacin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Neomycin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1-acarbose.htm">Acarbose</a></td><td><p><span></span> <span>neomycin</span> <span>possibly enhances hypoglycaemic effect of</span> <span>acarbose</span><span>, also severity of gastro-intestinal effects increased</span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span>experience in anticoagulant clinics suggests that INR possibly altered when </span><span>neomycin</span> <span>(given for local action on gut) is given with</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>neomycin</span> <span>reduces absorption of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td><p><span></span> <span>neomycin</span> <span>possibly reduces absorption of</span> <span>methotrexate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span>experience in anticoagulant clinics suggests that INR possibly altered when </span><span>neomycin</span> <span>(given for local action on gut) is given with</span> <span>phenindione</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int176-phenoxymethylpenicillin.htm">Phenoxymethylpenicillin</a></td><td><p><span></span> <span>neomycin</span> <span>reduces absorption of</span> <span>phenoxymethylpenicillin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1074-sorafenib.htm">Sorafenib</a></td><td><p><span></span> <span>neomycin</span> <span>reduces bioavailability of</span> <span>sorafenib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int833-vitamin-a.htm">Vitamin A</a></td><td><p><span></span> <span>neomycin</span> <span>possibly reduces absorption of</span> <span>vitamin A</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Streptomycin</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Tobramycin</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Capreomycin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int128-aminoglycosides.htm">Aminoglycosides</a></td><td><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>capreomycin</span> <span>given with</span> <span>aminoglycosides</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int190-colistimethate-sodium.htm">Colistimethate Sodium</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>capreomycin</span> <span>given with</span> <span>colistimethate sodium</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int512-platinum-compounds.htm">Platinum Compounds</a></td><td><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>capreomycin</span> <span>given with</span> <span>platinum compounds</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int189-polymyxins.htm">Polymyxins</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>capreomycin</span> <span>given with</span> <span>polymyxins</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int218-vancomycin.htm">Vancomycin</a></td><td><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>capreomycin</span> <span>given with</span> <span>vancomycin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Carbapenems</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td class="cAI"><p><span></span> <span>carbapenems</span> <span>reduce plasma concentration of</span> <span>valproate</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Doripenem</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>doripenem</span> <span>reduced by</span> <span>probenecid</span> <span>(manufacturers of <span>doripenem</span> advise avoid concomitant use)</span></p></td><td></td></tr></tbody></table><p><strong>Ertapenem</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Imipenem with Cilastatin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int395-ganciclovir.htm">Ganciclovir</a></td><td class="cAI"><p><span>increased risk of convulsions when </span><span>imipenem with cilastatin</span> <span>given with</span> <span>ganciclovir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature</p></div></td></tr></tbody></table><p><strong>Meropenem</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>meropenem</span> <span>reduced by</span> <span>probenecid</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Cephalosporins</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int128-aminoglycosides.htm">Aminoglycosides</a></td><td><p><span>possible increased risk of nephrotoxicity when </span><span>cephalosporins</span> <span>given with</span> <span>aminoglycosides</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>cephalosporins</span> <span>possibly enhance anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>cephalosporins</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Ceftaroline</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Cefaclor</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>cefaclor</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr></tbody></table><p><strong>Cefadroxil</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Cefalexin</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Cefixime</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Cefotaxime</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Cefpodoxime</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>cefpodoxime</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td><p><span>absorption of </span><span>cefpodoxime</span> <span>reduced by</span> <span>histamine H<sub>2</sub>-antagonists</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Cefradine</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Ceftazidime</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Ceftriaxone</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Cefuroxime</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Chloramphenicol</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>chloramphenicol</span> <span>possibly increases plasma concentration of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>chloramphenicol</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>chloramphenicol</span> <span>with</span> <span>clozapine</span> <span>(increased risk of agranulocytosis)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>chloramphenicol</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1007-hydroxocobalamin.htm">Hydroxocobalamin</a></td><td><p><span></span> <span>chloramphenicol</span> <span>reduces response to</span> <span>hydroxocobalamin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>metabolism of </span><span>chloramphenicol</span> <span>possibly accelerated by</span> <span>phenobarbital</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>chloramphenicol</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span><span>chloramphenicol</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td class="cAI"><p><span></span> <span>chloramphenicol</span> <span>enhances effects of</span> <span>sulfonylureas</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>chloramphenicol</span> <span>possibly increases plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr></tbody></table><p><strong>Clindamycin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int620-muscle-relaxants-non-depolarising.htm">Muscle Relaxants, non-depolarising</a></td><td class="cAI"><p><span></span> <span>clindamycin</span> <span>enhances effects of</span> <span>non-depolarising muscle relaxants</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int647-neostigmine.htm">Neostigmine</a></td><td><p><span></span> <span>clindamycin</span> <span>antagonises effects of</span> <span>neostigmine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int648-pyridostigmine.htm">Pyridostigmine</a></td><td><p><span></span> <span>clindamycin</span> <span>antagonises effects of</span> <span>pyridostigmine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td class="cAI"><p><span></span> <span>clindamycin</span> <span>enhances effects of</span> <span>suxamethonium</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Cycloserine</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td class="cAI"><p><span>increased risk of convulsions when </span><span>cycloserine</span> <span>given with</span> <span>alcohol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int165-isoniazid.htm">Isoniazid</a></td><td><p><span>increased risk of CNS toxicity when </span><span>cycloserine</span> <span>given with</span> <span>isoniazid</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Dapsone</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>dapsone</span> <span>reduced by</span> <span>probenecid</span> <span>(increased risk of side-effects)</span></p></td><td></td></tr><tr><td><a href="bnf_int199-rifamycins.htm">Rifamycins</a></td><td><p><span>plasma concentration of </span><span>dapsone</span> <span>reduced by</span> <span>rifamycins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>dapsone</span> <span>given with</span> <span>saquinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td><p><span>plasma concentration of both drugs may increase when </span><span>dapsone</span> <span>given with</span> <span>trimethoprim</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Fusidic Acid</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span><span>fusidic acid</span> <span>given with</span> <span>ritonavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span><span>fusidic acid</span> <span>given with</span> <span>saquinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int600-statins.htm">Statins</a></td><td class="cAI"><p><span>risk of myopathy and rhabdomyolysis when </span><span>fusidic acid</span> <span>given with</span> <span>statins</span><span>—avoid concomitant use and for 7 days after last <span>fusidic acid</span> dose</span></p></td><td></td></tr><tr><td><a href="bnf_int1127-sugammadex.htm">Sugammadex</a></td><td><p><span></span> <span>fusidic acid</span> <span>possibly reduces response to</span> <span>sugammadex</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Isoniazid</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>isoniazid</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>isoniazid</span> <span>increases plasma concentration of</span> <span>carbamazepine</span> <span>(also possibly increased <span>isoniazid</span> hepatotoxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span>plasma concentration of </span><span>isoniazid</span> <span>possibly reduced by</span> <span>corticosteroids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int160-cycloserine.htm">Cycloserine</a></td><td><p><span>increased risk of CNS toxicity when </span><span>isoniazid</span> <span>given with</span> <span>cycloserine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td><p><span></span> <span>isoniazid</span> <span>inhibits the metabolism of</span> <span>diazepam</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int523-disulfiram.htm">Disulfiram</a></td><td><p><span></span> <span>isoniazid</span> <span>possibly increases CNS effects of</span> <span>disulfiram</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int281-ethosuximide.htm">Ethosuximide</a></td><td class="cAI"><p><span></span> <span>isoniazid</span> <span>inhibits metabolism of</span> <span>ethosuximide</span> <span>(increased plasma concentration and risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span></span> <span>isoniazid</span> <span>possibly reduces plasma concentration of</span> <span>ketoconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int558-levodopa.htm">Levodopa</a></td><td><p><span></span> <span>isoniazid</span> <span>possibly reduces effects of</span> <span>levodopa</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>isoniazid</span> <span>possibly inhibits metabolism of</span> <span>phenytoin</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>isoniazid</span> <span>possibly increases plasma concentration of</span> <span>theophylline</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Linezolid</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Linezolid is a reversible, non-selective MAO inhibitor—see interactions of MAOIs</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>linezolid</span> <span>reduced by</span> <span>rifampicin</span> <span>(possible therapeutic failure of <span>linezolid</span>)</span></p></td><td></td></tr></tbody></table><p><strong>Macrolides</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> <em>See also</em> Telithromycin</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span><span>macrolides</span> <span>advised by manufacturer of</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int556-bromocriptine.htm">Bromocriptine</a></td><td><p><span></span> <span>macrolides</span> <span>possibly increase plasma concentration of</span> <span>bromocriptine</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int557-cabergoline.htm">Cabergoline</a></td><td><p><span></span> <span>macrolides</span> <span>possibly increase plasma concentration of</span> <span>cabergoline</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>macrolides</span> <span>possibly inhibit metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>macrolides</span> <span>increase plasma concentration of</span> <span>digoxin</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span><span>macrolides</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span><span>macrolides</span> <span>given with</span> <span>ergotamine and methysergide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span></span> <span>macrolides</span> <span>possibly inhibit metabolism of</span> <span>mizolastine</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td class="cAI"><p><span>avoidance of </span><span>macrolides</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span>(possible risk of ventricular arrhythmias)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td class="cAI"><p><span>avoidance of </span><span>macrolides</span> <span>advised by manufacturer of</span> <span>reboxetine</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Azithromycin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>azithromycin</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>azithromycin</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>azithromycin</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span></span> <span>azithromycin</span> <span>possibly increases plasma concentration of</span> <span>disopyramide</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>increased risk of side-effects including neutropenia when </span><span>azithromycin</span> <span>given with</span> <span>rifabutin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>azithromycin</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Clarithromycin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>aprepitant</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>plasma concentration of both drugs increased when </span><span>clarithromycin</span> <span>given with</span> <span>atazanavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1235-axitinib.htm">Axitinib</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>axitinib</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span><span>clarithromycin</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly inhibits metabolism of</span> <span>calcium-channel blockers</span> <span>(increased risk of side-effects)</span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1240-crizotinib.htm">Crizotinib</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>crizotinib</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>disopyramide</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span><span>clarithromycin</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>increased risk of rash when </span><span>clarithromycin</span> <span>given with</span> <span>efavirenz</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int963-eletriptan.htm">Eletriptan</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>eletriptan</span> <span>(risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>eplerenone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>etravirine</span><span>, also plasma concentration of <span>clarithromycin</span> reduced</span></p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of <span>fesoterodine</span> advises dose reduction when </span><span>clarithromycin</span> <span>given with</span> <span>fesoterodine</span><span>—consult <span>fesoterodine</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int1226-fidaxomicin.htm">Fidaxomicin</a></td><td><p><span>avoidance of </span><span>clarithromycin</span> <span>advised by manufacturer of</span> <span>fidaxomicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>ivabradine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1106-lenalidomide.htm">Lenalidomide</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>lenalidomide</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>maraviroc</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int492-methylprednisolone.htm">Methylprednisolone</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>methylprednisolone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>inhibits metabolism of</span> <span>midazolam</span> <span>(increased plasma concentration  with increased sedation)</span></p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span><span>clarithromycin</span> <span>reduced by</span> <span>nevirapine</span> <span>(but concentration of an active metabolite increased), also plasma concentration of <span>nevirapine</span> increased</span></p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td class="cAI"><p><span>avoidance of </span><span>clarithromycin</span> <span>advised by manufacturer of</span> <span>nilotinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td><p><span>plasma concentration of both drugs increased when </span><span>clarithromycin</span> <span>given with</span> <span>omeprazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span><span>clarithromycin</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>clarithromycin</span> <span>inhibits metabolism of</span> <span>phenytoin</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>clarithromycin</span> <span>given with</span> <span>pimozide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int604-pravastatin.htm">Pravastatin</a></td><td><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>pravastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td><p><span></span> <span>clarithromycin</span> <span>enhances effects of</span> <span>repaglinide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span></p></td><td></td></tr><tr><td><a href="bnf_int199-rifamycins.htm">Rifamycins</a></td><td><p><span>plasma concentration of </span><span>clarithromycin</span> <span>reduced by</span> <span>rifamycins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span>avoidance of </span><span>clarithromycin</span> <span>advised by manufacturer of</span> <span>rilpivirine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly increased)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>clarithromycin</span> <span>increased by</span> <span>ritonavir</span> <span>(reduce dose of <span>clarithromycin</span> in renal impairment)</span></p></td><td></td></tr><tr><td><a href="bnf_int1231-ruxolitinib.htm">Ruxolitinib</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>clarithromycin</span> <span>given with</span> <span>ruxolitinib</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>clarithromycin</span> <span>given with</span> <span>saquinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>sildenafil</span><span>—reduce initial dose of <span>sildenafil</span></span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>clarithromycin</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>sirolimus</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>tadalafil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of both drugs possibly increased when </span><span>clarithromycin</span> <span>given with</span> <span>telaprevir</span> <span>(increased risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>theophylline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td class="cAI"><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>ticagrelor</span><span>—manufacturer of <span>ticagrelor</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>clarithromycin</span> <span>increased by</span> <span>tipranavir</span> <span>(reduce dose of <span>clarithromycin</span> in renal impairment), also <span>clarithromycin</span> increases plasma concentration of <span>tipranavir</span></span></p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span><span>clarithromycin</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int255-trazodone.htm">Trazodone</a></td><td><p><span></span> <span>clarithromycin</span> <span>possibly increases plasma concentration of</span> <span>trazodone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1085-vinorelbine.htm">Vinorelbine</a></td><td class="cAI"><p><span>possible increased risk of neutropenia when </span><span>clarithromycin</span> <span>given with</span> <span>vinorelbine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td><p><span></span> <span>clarithromycin</span> <span>tablets reduce absorption of</span> <span>zidovudine</span> <span>(give at least 2 hours apart)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Erythromycin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>alfentanil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when <em>parenteral</em></span> <span>erythromycin</span> <span>given with</span> <span>amiodarone</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int809-amisulpride.htm">Amisulpride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>erythromycin</span> <span>given with</span> <span>amisulpride</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>erythromycin</span> <span>given with</span> <span>arsenic trioxide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when <em>parenteral</em></span> <span>erythromycin</span> <span>given with</span> <span>atomoxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span><span>erythromycin</span> <span>given with</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1235-axitinib.htm">Axitinib</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>axitinib</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int556-bromocriptine.htm">Bromocriptine</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>bromocriptine</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>buspirone</span> <span>(reduce dose of <span>buspirone</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int557-cabergoline.htm">Cabergoline</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>cabergoline</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>possibly inhibits metabolism of</span> <span>calcium-channel blockers</span> <span>(increased risk of side-effects)</span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int940-cilostazol.htm">Cilostazol</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>cilostazol</span> <span>(consider reducing dose of <span>cilostazol</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span><span>erythromycin</span> <span>increased by</span> <span>cimetidine</span> <span>(increased risk of toxicity, including deafness)</span></p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>clozapine</span> <span>(possible increased risk of convulsions)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span></p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly inhibits metabolism of</span> <span>corticosteroids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>darifenacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1172-dienogest.htm">Dienogest</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>dienogest</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>disopyramide</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int516-docetaxel.htm">Docetaxel</a></td><td><p><span><em>in vitro</em> studies suggest a possible interaction between </span><span>erythromycin</span> <span>and</span> <span>docetaxel</span> <span>(consult <span>docetaxel</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int553-domperidone.htm">Domperidone</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>erythromycin</span> <span>given with</span> <span>domperidone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>dronedarone</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int963-eletriptan.htm">Eletriptan</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>eletriptan</span> <span>(risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>(reduce dose of <span>eplerenone</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int640-estradiol.htm">Estradiol</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>estradiol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>everolimus</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1226-fidaxomicin.htm">Fidaxomicin</a></td><td><p><span>avoidance of </span><span>erythromycin</span> <span>advised by manufacturer of</span> <span>fidaxomicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>avoidance of </span><span>erythromycin</span> <span>advised by manufacturer of</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int915-galantamine.htm">Galantamine</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>galantamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>erythromycin</span> <span>given with</span> <span>ivabradine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int846-lercanidipine.htm">Lercanidipine</a></td><td><p><span>avoidance of </span><span>erythromycin</span> <span>advised by manufacturer of</span> <span>lercanidipine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int309-loratadine.htm">Loratadine</a></td><td><p><span>manufacturer of <span>loratadine</span> advises </span><span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>loratadine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int492-methylprednisolone.htm">Methylprednisolone</a></td><td><p><span></span> <span>erythromycin</span> <span>inhibits the metabolism of</span> <span>methylprednisolone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>inhibits metabolism of</span> <span>midazolam</span> <span>(increased plasma concentration  with increased sedation)</span></p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>inhibits metabolism of</span> <span>mizolastine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when <em>parenteral</em></span> <span>erythromycin</span> <span>given with</span> <span>moxifloxacin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when <em>parenteral</em></span> <span>erythromycin</span> <span>given with</span> <span>pentamidine isetionate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>erythromycin</span> <span>given with</span> <span>pimozide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int604-pravastatin.htm">Pravastatin</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>pravastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>rifabutin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span></p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span>avoidance of </span><span>erythromycin</span> <span>advised by manufacturer of</span> <span>rilpivirine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly increased)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>erythromycin</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td><p><span></span> <span>erythromycin</span> <span>reduces plasma concentration of</span> <span>rosuvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1155-rupatadine.htm">Rupatadine</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>rupatadine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>erythromycin</span> <span>given with</span> <span>saquinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>sildenafil</span><span>—reduce initial dose of <span>sildenafil</span></span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>erythromycin</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span><span>erythromycin</span> <span>given with</span> <span>sirolimus</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int371-sulpiride.htm">Sulpiride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when <em>parenteral</em></span> <span>erythromycin</span> <span>given with</span> <span>sulpiride</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>tadalafil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of both drugs possibly increased when </span><span>erythromycin</span> <span>given with</span> <span>telaprevir</span> <span>(increased risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>theophylline</span> <span>(also <span>theophylline</span> may reduce absorption of <em>oral</em><span>erythromycin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>ticagrelor</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span><span>erythromycin</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly inhibits metabolism of</span> <span>valproate</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when <em>parenteral</em></span> <span>erythromycin</span> <span>given with</span> <span>vandetanib</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>vardenafil</span> <span>(reduce dose of <span>vardenafil</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1002-vinblastine.htm">Vinblastine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases toxicity of</span> <span>vinblastine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int859-zafirlukast.htm">Zafirlukast</a></td><td><p><span></span> <span>erythromycin</span> <span>reduces plasma concentration of</span> <span>zafirlukast</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int426-zopiclone.htm">Zopiclone</a></td><td><p><span></span> <span>erythromycin</span> <span>inhibits the metabolism of</span> <span>zopiclone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int390-zuclopenthixol.htm">Zuclopenthixol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when <em>parenteral</em></span> <span>erythromycin</span> <span>given with</span> <span>zuclopenthixol</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Methenamine</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td class="cAI"><p><span>effects of </span><span>methenamine</span> <span>antagonised by</span> <span>acetazolamide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>avoid concomitant use of </span><span>methenamine</span> <span>with</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int800-potassium-citrate.htm">Potassium Citrate</a></td><td><p><span>avoid concomitant use of </span><span>methenamine</span> <span>with</span> <span>potassium citrate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1192-sodium-citrate.htm">Sodium Citrate</a></td><td><p><span>avoid concomitant use of </span><span>methenamine</span> <span>with</span> <span>sodium citrate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int203-sulfonamides.htm">Sulfonamides</a></td><td class="cAI"><p><span>increased risk of crystalluria when </span><span>methenamine</span> <span>given with</span> <span>sulfonamides</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Monobactams</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Aztreonam</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>aztreonam</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr></tbody></table><p><strong>Nitrofurantoin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int113-magnesium-salts-oral.htm">Magnesium Salts (oral)</a></td><td><p><span>absorption of </span><span>nitrofurantoin</span> <span>reduced by</span> <span>oral magnesium salts</span> <span>(as magnesium trisilicate)</span></p></td><td></td></tr><tr><td><a href="bnf_int196-nalidixic-acid.htm">Nalidixic Acid</a></td><td><p><span></span> <span>nitrofurantoin</span> <span>possibly antagonises effects of</span> <span>nalidixic acid</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>nitrofurantoin</span> <span>reduced by</span> <span>probenecid</span> <span>(increased risk of side-effects)</span></p></td><td></td></tr><tr><td><a href="bnf_int689-sulfinpyrazone.htm">Sulfinpyrazone</a></td><td><p><span>excretion of </span><span>nitrofurantoin</span> <span>reduced by</span> <span>sulfinpyrazone</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr></tbody></table><p><strong>Nitroimidazoles</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Metronidazole</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions do not apply to topical metronidazole preparations </p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>disulfiram-like reaction when </span><span>metronidazole</span> <span>given with</span> <span>alcohol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int993-busulfan.htm">Busulfan</a></td><td class="cAI"><p><span></span> <span>metronidazole</span> <span>increases plasma concentration of</span> <span>busulfan</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span><span>metronidazole</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>metronidazole</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int523-disulfiram.htm">Disulfiram</a></td><td><p><span>psychotic reaction reported when </span><span>metronidazole</span> <span>given with</span> <span>disulfiram</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int509-fluorouracil.htm">Fluorouracil</a></td><td><p><span></span> <span>metronidazole</span> <span>inhibits metabolism of</span> <span>fluorouracil</span> <span>(increased toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span></span> <span>metronidazole</span> <span>increases risk of</span> <span>lithium</span> <span>toxicity</span></p></td><td></td></tr><tr><td><a href="bnf_int520-mycophenolate.htm">Mycophenolate</a></td><td><p><span></span> <span>metronidazole</span> <span>possibly reduces bioavailability of</span> <span>mycophenolate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>metabolism of </span><span>metronidazole</span> <span>accelerated by</span> <span>phenobarbital</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>metronidazole</span> <span>possibly inhibits metabolism of</span> <span>phenytoin</span> <span>(increased plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Tinidazole</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>possibility of disulfiram-like reaction when </span><span>tinidazole</span> <span>given with</span> <span>alcohol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>tinidazole</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Penicillins</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span>an interaction between broad-spectrum </span><span>penicillins</span> <span>and</span> <span>coumarins</span> <span>has not been demonstrated in studies, but common experience in anticoagulant clinics is that INR can be altered</span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td><p><span></span> <span>penicillins</span> <span>reduce excretion of</span> <span>methotrexate</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td><p><span>an interaction between broad-spectrum </span><span>penicillins</span> <span>and</span> <span>phenindione</span> <span>has not been demonstrated in studies, but common experience in anticoagulant clinics is that INR can be altered</span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>penicillins</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int689-sulfinpyrazone.htm">Sulfinpyrazone</a></td><td><p><span>excretion of </span><span>penicillins</span> <span>reduced by</span> <span>sulfinpyrazone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int209-tetracyclines.htm">Tetracyclines</a></td><td><p><span>effects of </span><span>penicillins</span> <span>possibly antagonised by</span> <span>tetracyclines</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Temocillin</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Amoxicillin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int22-allopurinol.htm">Allopurinol</a></td><td><p><span>increased risk of rash when </span><span>amoxicillin</span> <span>given with</span> <span>allopurinol</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Co-amoxiclav</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Ampicillin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int22-allopurinol.htm">Allopurinol</a></td><td><p><span>increased risk of rash when </span><span>ampicillin</span> <span>given with</span> <span>allopurinol</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Benzylpenicillin</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Co-fluampicil</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><div class="cG"><p><strong>Note:</strong> Co-fluampicil interactions as for ampicillin and flucloxacillin</p></div><p><strong>Flucloxacillin</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Phenoxymethylpenicillin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int133-neomycin.htm">Neomycin</a></td><td><p><span>absorption of </span><span>phenoxymethylpenicillin</span> <span>reduced by</span> <span>neomycin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Piperacillin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int620-muscle-relaxants-non-depolarising.htm">Muscle Relaxants, non-depolarising</a></td><td><p><span></span> <span>piperacillin</span> <span>enhances effects of</span> <span>non-depolarising muscle relaxants</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td><p><span></span> <span>piperacillin</span> <span>enhances effects of</span> <span>suxamethonium</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Pivmecillinam</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td class="cAI"><p><span>manufacturer of </span><span>pivmecillinam</span> <span>advises avoid concomitant use with</span> <span>valproate</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Ticarcillin</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Polymyxins</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int128-aminoglycosides.htm">Aminoglycosides</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>polymyxins</span> <span>given with</span> <span>aminoglycosides</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>polymyxins</span> <span>given with</span> <span>amphotericin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int137-capreomycin.htm">Capreomycin</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>polymyxins</span> <span>given with</span> <span>capreomycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span><span>polymyxins</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td class="cAI"><p><span>increased risk of otoxicity when </span><span>polymyxins</span> <span>given with</span> <span>loop diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int620-muscle-relaxants-non-depolarising.htm">Muscle Relaxants, non-depolarising</a></td><td class="cAI"><p><span></span> <span>polymyxins</span> <span>enhance effects of</span> <span>non-depolarising muscle relaxants</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int647-neostigmine.htm">Neostigmine</a></td><td class="cAI"><p><span></span> <span>polymyxins</span> <span>antagonise effects of</span> <span>neostigmine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int512-platinum-compounds.htm">Platinum Compounds</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity and possibly of ototoxicity when </span><span>polymyxins</span> <span>given with</span> <span>platinum compounds</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int648-pyridostigmine.htm">Pyridostigmine</a></td><td class="cAI"><p><span></span> <span>polymyxins</span> <span>antagonise effects of</span> <span>pyridostigmine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td class="cAI"><p><span></span> <span>polymyxins</span> <span>enhance effects of</span> <span>suxamethonium</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int218-vancomycin.htm">Vancomycin</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>polymyxins</span> <span>given with</span> <span>vancomycin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Colistimethate Sodium</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int128-aminoglycosides.htm">Aminoglycosides</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>colistimethate sodium</span> <span>given with</span> <span>aminoglycosides</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int137-capreomycin.htm">Capreomycin</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>colistimethate sodium</span> <span>given with</span> <span>capreomycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int218-vancomycin.htm">Vancomycin</a></td><td><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>colistimethate sodium</span> <span>given with</span> <span>vancomycin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Polymyxin B</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Pyrazinamide</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span></span> <span>pyrazinamide</span> <span>antagonises effects of</span> <span>probenecid</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int689-sulfinpyrazone.htm">Sulfinpyrazone</a></td><td><p><span></span> <span>pyrazinamide</span> <span>antagonises effects of</span> <span>sulfinpyrazone</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Quinolones</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span><span>quinolones</span> <span>advised by manufacturer of</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span><span>quinolones</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1092-lanthanum.htm">Lanthanum</a></td><td><p><span>absorption of </span><span>quinolones</span> <span>possibly reduced by</span> <span>lanthanum</span> <span>(give at least 2 hours before or 4 hours after <span>lanthanum</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>possible increased risk of convulsions when </span><span>quinolones</span> <span>given with</span> <span>NSAIDs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int1026-strontium-ranelate.htm">Strontium Ranelate</a></td><td><p><span>absorption of </span><span>quinolones</span> <span>reduced by</span> <span>strontium ranelate</span> <span>(manufacturer of <span>strontium ranelate</span> advises avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span>possible increased risk of convulsions when </span><span>quinolones</span> <span>given with</span> <span>theophylline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int575-zolmitriptan.htm">Zolmitriptan</a></td><td><p><span></span> <span>quinolones</span> <span>possibly inhibit metabolism of</span> <span>zolmitriptan</span> <span>(reduce dose of <span>zolmitriptan</span>)</span></p></td><td></td></tr></tbody></table><p><strong>Moxifloxacin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>amiodarone</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>moxifloxacin</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>tricyclics</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>arsenic trioxide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>atomoxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int385-benperidol.htm">Benperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>benperidol</span><span>—manufacturer of <span>benperidol</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int335-chloroquine-and-hydroxychloroquine.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>chloroquine and hydroxychloroquine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>disopyramide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>droperidol</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with <em>parenteral</em></span> <span>erythromycin</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>haloperidol</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int587-iron.htm">Iron</a></td><td><p><span>absorption of </span><span>moxifloxacin</span> <span>reduced by <em>oral</em></span> <span>iron</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>mefloquine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>mizolastine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>pentamidine isetionate</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int373-phenothiazines.htm">Phenothiazines</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>phenothiazines</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>pimozide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td class="cAI"><p><span>avoidance of </span><span>moxifloxacin</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span>(possible risk of ventricular arrhythmias)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>quinine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>saquinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>sotalol</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int755-sucralfate.htm">Sucralfate</a></td><td><p><span>absorption of </span><span>moxifloxacin</span> <span>reduced by</span> <span>sucralfate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>vandetanib</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int803-zinc.htm">Zinc</a></td><td><p><span>absorption of </span><span>moxifloxacin</span> <span>reduced by</span> <span>zinc</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int390-zuclopenthixol.htm">Zuclopenthixol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>moxifloxacin</span> <span>given with</span> <span>zuclopenthixol</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Ciprofloxacin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1145-agomelatine.htm">Agomelatine</a></td><td class="cAI"><p><span>avoidance of </span><span>ciprofloxacin</span> <span>advised by manufacturer of</span> <span>agomelatine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>ciprofloxacin</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int465-calcium-salts.htm">Calcium Salts</a></td><td><p><span>absorption of </span><span>ciprofloxacin</span> <span>reduced by</span> <span>calcium salts</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>see also</em> Antacids</p></div></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>ciprofloxacin</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td><p><span></span> <span>ciprofloxacin</span> <span>increases plasma concentration of</span> <span>clozapine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>ciprofloxacin</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int831-dairy-products.htm">Dairy Products</a></td><td><p><span>absorption of </span><span>ciprofloxacin</span> <span>reduced by</span> <span>dairy products</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td class="cAI"><p><span></span> <span>ciprofloxacin</span> <span>inhibits metabolism of</span> <span>duloxetine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1048-erlotinib.htm">Erlotinib</a></td><td><p><span></span> <span>ciprofloxacin</span> <span>increases plasma concentration of</span> <span>erlotinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int587-iron.htm">Iron</a></td><td><p><span>absorption of </span><span>ciprofloxacin</span> <span>reduced by <em>oral</em></span> <span>iron</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td><p><span></span> <span>ciprofloxacin</span> <span>possibly reduces excretion of</span> <span>methotrexate</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int366-olanzapine.htm">Olanzapine</a></td><td><p><span></span> <span>ciprofloxacin</span> <span>possibly increases plasma concentration of</span> <span>olanzapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>ciprofloxacin</span> <span>increases or decreases plasma concentration of</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>ciprofloxacin</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td><p><span></span> <span>ciprofloxacin</span> <span>increases plasma concentration of</span> <span>rasagiline</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int686-ropinirole.htm">Ropinirole</a></td><td><p><span></span> <span>ciprofloxacin</span> <span>inhibits metabolism of</span> <span>ropinirole</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int1065-sevelamer.htm">Sevelamer</a></td><td><p><span>bioavailability of </span><span>ciprofloxacin</span> <span>reduced by</span> <span>sevelamer</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int755-sucralfate.htm">Sucralfate</a></td><td><p><span>absorption of </span><span>ciprofloxacin</span> <span>reduced by</span> <span>sucralfate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>ciprofloxacin</span> <span>increases plasma concentration of</span> <span>theophylline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int805-tizanidine.htm">Tizanidine</a></td><td class="cAI"><p><span></span> <span>ciprofloxacin</span> <span>increases plasma concentration of</span> <span>tizanidine</span> <span>(increased risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int803-zinc.htm">Zinc</a></td><td><p><span>absorption of </span><span>ciprofloxacin</span> <span>reduced by</span> <span>zinc</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Levofloxacin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>levofloxacin</span> <span>given with</span> <span>amiodarone</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>levofloxacin</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>levofloxacin</span> <span>given with</span> <span>arsenic trioxide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>levofloxacin</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int587-iron.htm">Iron</a></td><td><p><span>absorption of </span><span>levofloxacin</span> <span>reduced by <em>oral</em></span> <span>iron</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td><p><span></span> <span>levofloxacin</span> <span>possibly enhances anticoagulant effect of</span> <span>phenindione</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int755-sucralfate.htm">Sucralfate</a></td><td><p><span>absorption of </span><span>levofloxacin</span> <span>reduced by</span> <span>sucralfate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int803-zinc.htm">Zinc</a></td><td><p><span>absorption of </span><span>levofloxacin</span> <span>reduced by</span> <span>zinc</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Nalidixic Acid</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>nalidixic acid</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int503-melphalan.htm">Melphalan</a></td><td><p><span></span> <span>nalidixic acid</span> <span>increases risk of</span> <span>melphalan</span> <span>toxicity</span></p></td><td></td></tr><tr><td><a href="bnf_int173-nitrofurantoin.htm">Nitrofurantoin</a></td><td><p><span>effects of </span><span>nalidixic acid</span> <span>possibly antagonised by</span> <span>nitrofurantoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>nalidixic acid</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Norfloxacin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>norfloxacin</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>norfloxacin</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int831-dairy-products.htm">Dairy Products</a></td><td><p><span>absorption of </span><span>norfloxacin</span> <span>reduced by</span> <span>dairy products</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int270-glibenclamide.htm">Glibenclamide</a></td><td><p><span></span> <span>norfloxacin</span> <span>possibly enhances effects of</span> <span>glibenclamide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int587-iron.htm">Iron</a></td><td><p><span>absorption of </span><span>norfloxacin</span> <span>reduced by <em>oral</em></span> <span>iron</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int520-mycophenolate.htm">Mycophenolate</a></td><td><p><span></span> <span>norfloxacin</span> <span>possibly reduces bioavailability of</span> <span>mycophenolate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>norfloxacin</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int755-sucralfate.htm">Sucralfate</a></td><td><p><span>absorption of </span><span>norfloxacin</span> <span>reduced by</span> <span>sucralfate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>norfloxacin</span> <span>increases plasma concentration of</span> <span>theophylline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int805-tizanidine.htm">Tizanidine</a></td><td><p><span></span> <span>norfloxacin</span> <span>possibly increases plasma concentration of</span> <span>tizanidine</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int803-zinc.htm">Zinc</a></td><td><p><span>absorption of </span><span>norfloxacin</span> <span>reduced by</span> <span>zinc</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Ofloxacin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>ofloxacin</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>ofloxacin</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int587-iron.htm">Iron</a></td><td><p><span>absorption of </span><span>ofloxacin</span> <span>reduced by <em>oral</em></span> <span>iron</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int755-sucralfate.htm">Sucralfate</a></td><td><p><span>absorption of </span><span>ofloxacin</span> <span>reduced by</span> <span>sucralfate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int803-zinc.htm">Zinc</a></td><td><p><span>absorption of </span><span>ofloxacin</span> <span>reduced by</span> <span>zinc</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Rifamycins</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span></span> <span>rifamycins</span> <span>reduce plasma concentration of</span> <span>clarithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>corticosteroids</span> <span>(reduced effect)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>coumarins</span> <span>(reduced anticoagulant effect)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int161-dapsone.htm">Dapsone</a></td><td><p><span></span> <span>rifamycins</span> <span>reduce plasma concentration of</span> <span>dapsone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>disopyramide</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>phenytoin</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>possibly accelerate metabolism of</span> <span>sulfonylureas</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int275-tolbutamide.htm">Tolbutamide</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>tolbutamide</span> <span>(reduced effect)</span></p></td><td></td></tr></tbody></table><p><strong>Rifabutin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>possibly increased by</span> <span>triazoles</span> <span>(increased risk of uveitis—reduce <span>rifabutin</span> dose)</span></p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>possibly reduces plasma concentration of</span> <span>aripiprazole</span><span>—increase dose of <span>aripiprazole</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>increased by</span> <span>atazanavir</span> <span>(reduce dose of <span>rifabutin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int431-atovaquone.htm">Atovaquone</a></td><td><p><span>avoidance of concomitant </span><span>rifabutin</span> <span>advised by manufacturer of</span> <span>atovaquone</span> <span>(plasma concentration of both drugs reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int1235-axitinib.htm">Axitinib</a></td><td><p><span></span> <span>rifabutin</span> <span>possibly decreases plasma concentration of</span> <span>axitinib</span> <span>(increase dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int167-azithromycin.htm">Azithromycin</a></td><td class="cAI"><p><span>increased risk of side-effects including neutropenia when </span><span>rifabutin</span> <span>given with</span> <span>azithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span><span>rifabutin</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of  </span><span>rifabutin</span> <span>increased by</span> <span>clarithromycin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span></p></td><td></td></tr><tr><td><a href="bnf_int1240-crizotinib.htm">Crizotinib</a></td><td><p><span></span> <span>rifabutin</span> <span>possibly reduces plasma concentration of</span> <span>crizotinib</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>increased by</span> <span>darunavir</span> <span>(reduce dose of <span>rifabutin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span><span>rifabutin</span> <span>reduced by</span> <span>efavirenz</span><span>—increase dose of <span>rifabutin</span></span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>possibly increased by</span> <span>erythromycin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span>plasma concentration of both drugs reduced when </span><span>rifabutin</span> <span>given with</span> <span>etravirine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>increased by</span> <span>fluconazole</span> <span>(increased risk of uveitis—reduce <span>rifabutin</span> dose)</span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>increased by</span> <span>fosamprenavir</span> <span>(reduce dose of <span>rifabutin</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>increased by</span> <span>indinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>itraconazole</span><span>—manufacturer of <span>itraconazole</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span><span>rifabutin</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span><span>rifabutin</span> <span>possibly increased by</span> <span>nevirapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>increased by</span> <span>posaconazole</span> <span>(also plasma concentration of <span>posaconazole</span> reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>rilpivirine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of  </span><span>rifabutin</span> <span>increased by</span> <span>ritonavir</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>increased by</span> <span>saquinavir</span> <span>(also plasma concentration of <span>saquinavir</span> reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>sirolimus</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span></span> <span>rifabutin</span> <span>possibly reduces plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>rifabutin</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>increased by</span> <span>tipranavir</span> <span>(reduce dose of <span>rifabutin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1229-vemurafenib.htm">Vemurafenib</a></td><td><p><span>avoidance of </span><span>rifabutin</span> <span>advised by manufacturer of</span> <span>vemurafenib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rifabutin</span> <span>increased by</span> <span>voriconazole</span><span>, also <span>rifabutin</span> reduces plasma concentration of <span>voriconazole</span> (increase dose of <span>voriconazole</span> and also monitor for <span>rifabutin</span> toxicity)</span></p></td><td></td></tr></tbody></table><p><strong>Rifampicin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int907-abacavir.htm">Abacavir</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>abacavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>alfentanil</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int1099-aliskiren.htm">Aliskiren</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>aliskiren</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1233-ambrisentan.htm">Ambrisentan</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly increases plasma concentration of</span> <span>ambrisentan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>rifampicin</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>aprepitant</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>aripiprazole</span><span>—increase dose of <span>aripiprazole</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>atazanavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int431-atovaquone.htm">Atovaquone</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>atovaquone</span> <span>(and concentration of rifampicin increased)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1235-axitinib.htm">Axitinib</a></td><td><p><span></span> <span>rifampicin</span> <span>decreases plasma concentration of</span> <span>axitinib</span> <span>(increase dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int405-benzodiazepines.htm">Benzodiazepines</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly accelerates metabolism of</span> <span>benzodiazepines</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int443-bisoprolol.htm">Bisoprolol</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>bisoprolol</span> <span>(plasma concentration  significantly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>rifampicin</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span>(plasma concentration of <span>boceprevir</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>bosentan</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1242-brentuximab-vedotin.htm">Brentuximab vedotin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces effects of</span> <span>brentuximab vedotin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly accelerates metabolism of</span> <span>buspirone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span><span>rifampicin</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int445-carvedilol.htm">Carvedilol</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>carvedilol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int947-caspofungin.htm">Caspofungin</a></td><td><p><span></span> <span>rifampicin</span> <span>initially increases and then reduces plasma concentration of</span> <span>caspofungin</span> <span>(consider increasing dose of <span>caspofungin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int898-celecoxib.htm">Celecoxib</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>celecoxib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int446-celiprolol.htm">Celiprolol</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>celiprolol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int158-chloramphenicol.htm">Chloramphenicol</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>chloramphenicol</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>ciclosporin</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>cimetidine</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>clozapine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int88-codeine.htm">Codeine</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>codeine</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int1240-crizotinib.htm">Crizotinib</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>crizotinib</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>dabigatran etexilate</span><span>—manufacturer of <span>dabigatran etexilate</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>darunavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1077-dasatinib.htm">Dasatinib</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>dasatinib</span> <span>(reduced plasma  concentration—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1072-deferasirox.htm">Deferasirox</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>deferasirox</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>diazepam</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int64-diclofenac.htm">Diclofenac</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>diclofenac</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>diltiazem</span> <span>(plasma concentration  significantly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int212-doxycycline.htm">Doxycycline</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>doxycycline</span><span>—consider increasing dose of <span>doxycycline</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>dronedarone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>efavirenz</span><span>—increase dose of <span>efavirenz</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>eplerenone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1205-eribulin.htm">Eribulin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>eribulin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1048-erlotinib.htm">Erlotinib</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>erlotinib</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int960-etoricoxib.htm">Etoricoxib</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>etoricoxib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td><p><span>avoidance of </span><span>rifampicin</span> <span>advised by manufacturer of</span> <span>etravirine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>everolimus</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1047-exemestane.htm">Exemestane</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>exemestane</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int95-fentanyl.htm">Fentanyl</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>fentanyl</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of active metabolite of</span> <span>fesoterodine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int308-fexofenadine.htm">Fexofenadine</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces effects of</span> <span>fexofenadine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>fluconazole</span> <span>(reduced plasma concentration)</span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int603-fluvastatin.htm">Fluvastatin</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>fluvastatin</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>fosamprenavir</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int1170-gefitinib.htm">Gefitinib</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>gefitinib</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>haloperidol</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>imatinib</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int870-imidapril.htm">Imidapril</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of active metabolite of</span> <span>imidapril</span> <span>(reduced antihypertensive effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>indinavir</span> <span>(reduced plasma  concentration—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int472-isradipine.htm">Isradipine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>possibly accelerates metabolism of</span> <span>isradipine</span> <span>(possible significantly reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>itraconazole</span><span>—manufacturer of <span>itraconazole</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>ketoconazole</span> <span>(reduced plasma concentration), also plasma concentration of <span>rifampicin</span> may be reduced by <span>ketoconazole</span></span></p></td><td></td></tr><tr><td><a href="bnf_int283-lamotrigine.htm">Lamotrigine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>lamotrigine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span><span>rifampicin</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int891-leflunomide.htm">Leflunomide</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly increases plasma concentration of active metabolite of</span> <span>leflunomide</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</p></div></td></tr><tr><td><a href="bnf_int738-levothyroxine.htm">Levothyroxine</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>levothyroxine</span> <span>(may increase requirements for <span>levothyroxine</span> in hypothyroidism)</span></p></td><td></td></tr><tr><td><a href="bnf_int1210-linagliptin.htm">Linagliptin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces effects of</span> <span>linagliptin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int917-linezolid.htm">Linezolid</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>linezolid</span> <span>(possible therapeutic failure of <span>linezolid</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Linezolid is a reversible, non-selective MAO inhibitor—see interactions of MAOIs</p></div></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>lopinavir</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int108-losartan.htm">Losartan</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>losartan</span> <span>and its active metabolite</span></p></td><td></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>maraviroc</span><span>—consider increasing dose of <span>maraviroc</span></span></p></td><td></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>mefloquine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>methadone</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>metoprolol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int98-morphine.htm">Morphine</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>morphine</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int520-mycophenolate.htm">Mycophenolate</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of active metabolite of</span> <span>mycophenolate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int920-nateglinide.htm">Nateglinide</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>nateglinide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>nevirapine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int474-nicardipine.htm">Nicardipine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>possibly accelerates metabolism of</span> <span>nicardipine</span> <span>(possible significantly reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>nifedipine</span> <span>(plasma concentration  significantly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>nilotinib</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int476-nimodipine.htm">Nimodipine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>nimodipine</span> <span>(plasma concentration  significantly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int1045-ondansetron.htm">Ondansetron</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>ondansetron</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int901-oxycodone.htm">Oxycodone</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly accelerates metabolism of</span> <span>oxycodone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span><span>rifampicin</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span><span>rifampicin</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td><p><span>avoidance of </span><span>rifampicin</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>posaconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>propafenone</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int793-propranolol.htm">Propranolol</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>propranolol</span> <span>(plasma concentration  significantly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>quinine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1111-raltegravir.htm">Raltegravir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>raltegravir</span><span>—consider increasing dose of <span>raltegravir</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly antagonises hypoglycaemic effect of</span> <span>repaglinide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>rilpivirine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>rivaroxaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1190-roflumilast.htm">Roflumilast</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>roflumilast</span><span>—consider increasing dose of <span>roflumilast</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1231-ruxolitinib.htm">Ruxolitinib</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>ruxolitinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>saquinavir</span><span>, also risk of hepatotoxicity—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>simvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>sirolimus</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1074-sorafenib.htm">Sorafenib</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>sorafenib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1075-sunitinib.htm">Sunitinib</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>sunitinib</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>tadalafil</span><span>—manufacturer of <span>tadalafil</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int581-tamoxifen.htm">Tamoxifen</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>tamoxifen</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>telaprevir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>telithromycin</span> <span>(avoid during and for 2 weeks after <span>rifampicin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1137-temsirolimus.htm">Temsirolimus</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of active metabolite of</span> <span>temsirolimus</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> The main active metabolite of temsirolimus is sirolimus—<em>see also</em> interactions of sirolimus and consult product literature</p></div></td></tr><tr><td><a href="bnf_int292-terbinafine.htm">Terbinafine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>terbinafine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>theophylline</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int737-tibolone.htm">Tibolone</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>tibolone</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>ticagrelor</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int786-tinidazole.htm">Tinidazole</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>tinidazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>tipranavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int805-tizanidine.htm">Tizanidine</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>tizanidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1158-tolvaptan.htm">Tolvaptan</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>tolvaptan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>trimethoprim</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1163-ulipristal.htm">Ulipristal</a></td><td class="cAI"><p><span>avoidance of </span><span>rifampicin</span> <span>advised by manufacturer of</span> <span>ulipristal</span> <span>(contraceptive effect of <span>ulipristal</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td><p><span>avoidance of </span><span>rifampicin</span> <span>advised by manufacturer of</span> <span>vandetanib</span> <span>(plasma concentration of <span>vandetanib</span> reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int1229-vemurafenib.htm">Vemurafenib</a></td><td><p><span>avoidance of </span><span>rifampicin</span> <span>advised by manufacturer of</span> <span>vemurafenib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>verapamil</span> <span>(plasma concentration  significantly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int1181-vinflunine.htm">Vinflunine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>vinflunine</span><span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>voriconazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int904-zaleplon.htm">Zaleplon</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>zaleplon</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td><p><span>avoidance of </span><span>rifampicin</span> <span>advised by manufacturer of</span> <span>zidovudine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr><tr><td><a href="bnf_int425-zolpidem.htm">Zolpidem</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>zolpidem</span> <span>(reduced plasma concentration and reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int426-zopiclone.htm">Zopiclone</a></td><td><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>zopiclone</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Sulfonamides</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span><span>sulfonamides</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>sulfonamides</span> <span>with</span> <span>clozapine</span> <span>(increased risk of agranulocytosis)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>sulfonamides</span> <span>enhance anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int164-methenamine.htm">Methenamine</a></td><td class="cAI"><p><span>increased risk of crystalluria when </span><span>sulfonamides</span> <span>given with</span> <span>methenamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td><p><span></span> <span>sulfonamides</span> <span>increase risk of</span> <span>methotrexate</span> <span>toxicity</span></p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td><p><span></span> <span>sulfonamides</span> <span>possibly inhibit metabolism of</span> <span>phenindione</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>sulfonamides</span> <span>possibly increase plasma concentration of</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int661-potassium-aminobenzoate.htm">Potassium Aminobenzoate</a></td><td><p><span>effects of </span><span>sulfonamides</span> <span>inhibited by</span> <span>potassium aminobenzoate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int873-prilocaine.htm">Prilocaine</a></td><td><p><span>increased risk of methaemoglobinaemia when </span><span>sulfonamides</span> <span>given with</span> <span>prilocaine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int340-pyrimethamine.htm">Pyrimethamine</a></td><td class="cAI"><p><span>increased antifolate effect when </span><span>sulfonamides</span> <span>given with</span> <span>pyrimethamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td><p><span></span> <span>sulfonamides</span> <span>rarely enhance the effects of</span> <span>sulfonylureas</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int42-thiopental.htm">Thiopental</a></td><td><p><span></span> <span>sulfonamides</span> <span>enhance effects of</span> <span>thiopental</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Sulfadiazine</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>sulfadiazine</span> <span>possibly reduces plasma concentration of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Sulfadoxine</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Sulfamethoxazole</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td><p><span>possible increased risk of ventricular arrhythmias when </span><span>sulfamethoxazole</span> <span>(as co-trimoxazole) given with</span> <span>amiodarone</span><span>—manufacturer of <span>amiodarone</span> advises avoid concomitant use of co-trimoxazole</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int519-azathioprine.htm">Azathioprine</a></td><td class="cAI"><p><span>increased risk of haematological toxicity when </span><span>sulfamethoxazole</span> <span>(as co-trimoxazole) given with</span> <span>azathioprine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int510-mercaptopurine.htm">Mercaptopurine</a></td><td class="cAI"><p><span>increased risk of haematological toxicity when </span><span>sulfamethoxazole</span> <span>(as co-trimoxazole) given with</span> <span>mercaptopurine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span>increased risk of haematological toxicity when </span><span>sulfamethoxazole</span> <span>(as co-trimoxazole) given with</span> <span>methotrexate</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Tetracyclines</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>tetracyclines</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>tetracyclines</span> <span>possibly enhance anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int831-dairy-products.htm">Dairy Products</a></td><td><p><span>absorption of </span><span>tetracyclines</span> <span>(except doxycycline and minocycline) reduced by</span> <span>dairy products</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td><p><span>increased risk of ergotism when </span><span>tetracyclines</span> <span>given with</span> <span>ergotamine and methysergide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int587-iron.htm">Iron</a></td><td><p><span>absorption of </span><span>tetracyclines</span> <span>reduced by <em>oral</em></span> <span>iron</span><span>, also absorption of <em>oral</em><span>iron</span> reduced by <span>tetracyclines</span></span></p></td><td></td></tr><tr><td><a href="bnf_int14-kaolin.htm">Kaolin</a></td><td><p><span>absorption of </span><span>tetracyclines</span> <span>possibly reduced by</span> <span>kaolin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int174-penicillins.htm">Penicillins</a></td><td><p><span></span> <span>tetracyclines</span> <span>possibly antagonise effects of</span> <span>penicillins</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>tetracyclines</span> <span>possibly enhance anticoagulant effect of</span> <span>phenindione</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int10-quinapril.htm">Quinapril</a></td><td><p><span>absorption of </span><span>tetracyclines</span> <span>reduced by</span> <span>quinapril</span> <span>tablets (<span>quinapril</span> tablets contain magnesium carbonate)</span></p></td><td></td></tr><tr><td><a href="bnf_int682-retinoids.htm">Retinoids</a></td><td class="cAI"><p><span>possible increased risk of benign intracranial hypertension when </span><span>tetracyclines</span> <span>given with</span> <span>retinoids</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1026-strontium-ranelate.htm">Strontium Ranelate</a></td><td><p><span>absorption of </span><span>tetracyclines</span> <span>reduced by</span> <span>strontium ranelate</span> <span>(manufacturer of <span>strontium ranelate</span> advises avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int755-sucralfate.htm">Sucralfate</a></td><td><p><span>absorption of </span><span>tetracyclines</span> <span>reduced by</span> <span>sucralfate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td><p><span></span> <span>tetracyclines</span> <span>possibly enhance hypoglycaemic effect of</span> <span>sulfonylureas</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int756-tripotassium-dicitratobismuthate.htm">Tripotassium Dicitratobismuthate</a></td><td><p><span>absorption of </span><span>tetracyclines</span> <span>reduced by</span> <span>tripotassium dicitratobismuthate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int803-zinc.htm">Zinc</a></td><td><p><span>absorption of </span><span>tetracyclines</span> <span>reduced by</span> <span>zinc</span><span>, also absorption of <span>zinc</span> reduced by <span>tetracyclines</span></span></p></td><td></td></tr></tbody></table><p><strong>Demeclocycline</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Doxycycline</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>metabolism of </span><span>doxycycline</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td><p><span></span> <span>doxycycline</span> <span>increases risk of</span> <span>methotrexate</span> <span>toxicity</span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>metabolism of </span><span>doxycycline</span> <span>accelerated by</span> <span>phenobarbital</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>metabolism of </span><span>doxycycline</span> <span>accelerated by</span> <span>phenytoin</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>doxycycline</span> <span>reduced by</span> <span>rifampicin</span><span>—consider increasing dose of <span>doxycycline</span></span></p></td><td></td></tr></tbody></table><p><strong>Lymecycline</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>manufacturer of </span><span>lymecycline</span> <span>advises avoid concomitant use with</span> <span>diuretics</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Minocycline</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Oxytetracycline</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Tetracycline</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int431-atovaquone.htm">Atovaquone</a></td><td><p><span></span> <span>tetracycline</span> <span>reduces plasma concentration of</span> <span>atovaquone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int465-calcium-salts.htm">Calcium Salts</a></td><td><p><span>absorption of </span><span>tetracycline</span> <span>reduced by</span> <span>calcium salts</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>see also</em> Antacids</p></div></td></tr><tr><td><a href="bnf_int593-colestipol.htm">Colestipol</a></td><td><p><span>absorption of </span><span>tetracycline</span> <span>possibly reduced by</span> <span>colestipol</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorption </p></div></td></tr><tr><td><a href="bnf_int592-colestyramine.htm">Colestyramine</a></td><td><p><span>absorption of </span><span>tetracycline</span> <span>possibly reduced by</span> <span>colestyramine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</p></div></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td><p><span></span> <span>tetracycline</span> <span>increases risk of</span> <span>methotrexate</span> <span>toxicity</span></p></td><td></td></tr></tbody></table><p><strong>Teicoplanin</strong> belongs to <strong>Antibacterials</strong> but has no specific interaction information.</p><p><strong>Trimethoprim</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span>possible increased risk of hyperkalaemia when </span><span>trimethoprim</span> <span>given with</span> <span>ACE inhibitors</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td><p><span>possible increased risk of ventricular arrhythmias when </span><span>trimethoprim</span> <span>(as co-trimoxazole) given with</span> <span>amiodarone</span><span>—manufacturer of <span>amiodarone</span> advises avoid concomitant use of co-trimoxazole</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td><p><span>possible increased risk of hyperkalaemia when </span><span>trimethoprim</span> <span>given with</span> <span>angiotensin-II receptor antagonists</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int519-azathioprine.htm">Azathioprine</a></td><td class="cAI"><p><span>increased risk of haematological toxicity when </span><span>trimethoprim</span> <span>(also with co-trimoxazole) given with</span> <span>azathioprine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span><span>trimethoprim</span> <span>given with</span> <span>ciclosporin</span><span>, also plasma concentration of <span>ciclosporin</span> reduced by <em>intravenous</em><span>trimethoprim</span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>trimethoprim</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int161-dapsone.htm">Dapsone</a></td><td><p><span>plasma concentration of both drugs may increase when </span><span>trimethoprim</span> <span>given with</span> <span>dapsone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>trimethoprim</span> <span>possibly increases plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td><p><span>increased risk of hyperkalaemia when </span><span>trimethoprim</span> <span>given with</span> <span>eplerenone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int399-lamivudine.htm">Lamivudine</a></td><td><p><span></span> <span>trimethoprim</span> <span>(as co-trimoxazole) increases plasma concentration of</span> <span>lamivudine</span><span>—avoid concomitant use of high-dose co-trimoxazole</span></p></td><td></td></tr><tr><td><a href="bnf_int510-mercaptopurine.htm">Mercaptopurine</a></td><td class="cAI"><p><span>increased risk of haematological toxicity when </span><span>trimethoprim</span> <span>(also with co-trimoxazole) given with</span> <span>mercaptopurine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td class="cAI"><p><span>increased risk of haematological toxicity when </span><span>trimethoprim</span> <span>(also with co-trimoxazole) given with</span> <span>methotrexate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>trimethoprim</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span>(also increased antifolate effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int340-pyrimethamine.htm">Pyrimethamine</a></td><td class="cAI"><p><span>increased antifolate effect when </span><span>trimethoprim</span> <span>given with</span> <span>pyrimethamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td><p><span></span> <span>trimethoprim</span> <span>possibly enhances hypoglycaemic effect of</span> <span>repaglinide</span><span>—manufacturer advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>trimethoprim</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int549-spironolactone.htm">Spironolactone</a></td><td><p><span>possible increased risk of hyperkalaemia when </span><span>trimethoprim</span> <span>given with</span> <span>spironolactone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td><p><span></span> <span>trimethoprim</span> <span>rarely enhances the effects of</span> <span>sulfonylureas</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Vancomycin</strong> belongs to <strong>Antibacterials</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int128-aminoglycosides.htm">Aminoglycosides</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>vancomycin</span> <span>given with</span> <span>aminoglycosides</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td><p><span>possible increased risk of nephrotoxicity when </span><span>vancomycin</span> <span>given with</span> <span>amphotericin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int39-anaesthetics-general.htm">Anaesthetics, General</a></td><td><p><span>hypersensitivity-like reactions can occur when <em>intravenous</em></span> <span>vancomycin</span> <span>given with</span> <span>general anaesthetics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also</em> Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="PHP8495-general-anaesthesia.htm#PHP8498">section 15.1</a>



</p></div></td></tr><tr><td><a href="bnf_int137-capreomycin.htm">Capreomycin</a></td><td><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>vancomycin</span> <span>given with</span> <span>capreomycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span><span>vancomycin</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int877-cisplatin.htm">Cisplatin</a></td><td><p><span>increased risk of nephrotoxicity and possibly of ototoxicity when </span><span>vancomycin</span> <span>given with</span> <span>cisplatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int592-colestyramine.htm">Colestyramine</a></td><td><p><span>effects of <em>oral</em></span> <span>vancomycin</span> <span>antagonised by</span> <span>colestyramine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</p></div></td></tr><tr><td><a href="bnf_int190-colistimethate-sodium.htm">Colistimethate Sodium</a></td><td><p><span>increased risk of nephrotoxicity and ototoxicity when </span><span>vancomycin</span> <span>given with</span> <span>colistimethate sodium</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td class="cAI"><p><span>increased risk of otoxicity when </span><span>vancomycin</span> <span>given with</span> <span>loop diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int189-polymyxins.htm">Polymyxins</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>vancomycin</span> <span>given with</span> <span>polymyxins</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td class="cAI"><p><span></span> <span>vancomycin</span> <span>enhances effects of</span> <span>suxamethonium</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span>possible increased risk of nephrotoxicity when </span><span>vancomycin</span> <span>given with</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1069-tigecycline.htm" title="Tigecycline">Tigecycline</a></li><li><a href="bnf_int1061-daptomycin.htm" title="Daptomycin">Daptomycin</a></li><li><a href="bnf_int938-co-trimoxazole.htm" title="Co-trimoxazole">Co-trimoxazole</a></li><li><a href="bnf_int946-telithromycin.htm" title="Telithromycin">Telithromycin</a></li><li id="_bnf_int128-aminoglycosides"><a href="bnf_int128-aminoglycosides.htm" title="Aminoglycosides">Aminoglycosides</a></li><li><a href="bnf_int137-capreomycin.htm" title="Capreomycin">Capreomycin</a></li><li id="_bnf_int138-carbapenems"><a href="bnf_int138-carbapenems.htm" title="Carbapenems">Carbapenems</a></li><li id="_bnf_int141-cephalosporins"><a href="bnf_int141-cephalosporins.htm" title="Cephalosporins">Cephalosporins</a></li><li><a href="bnf_int158-chloramphenicol.htm" title="Chloramphenicol">Chloramphenicol</a></li><li><a href="bnf_int159-clindamycin.htm" title="Clindamycin">Clindamycin</a></li><li><a href="bnf_int160-cycloserine.htm" title="Cycloserine">Cycloserine</a></li><li><a href="bnf_int161-dapsone.htm" title="Dapsone">Dapsone</a></li><li><a href="bnf_int163-fusidic-acid.htm" title="Fusidic Acid">Fusidic Acid</a></li><li><a href="bnf_int165-isoniazid.htm" title="Isoniazid">Isoniazid</a></li><li><a href="bnf_int917-linezolid.htm" title="Linezolid">Linezolid</a></li><li id="_bnf_int166-macrolides"><a href="bnf_int166-macrolides.htm" title="Macrolides">Macrolides</a></li><li><a href="bnf_int164-methenamine.htm" title="Methenamine">Methenamine</a></li><li id="_bnf_int171-monobactams"><a href="bnf_int171-monobactams.htm" title="Monobactams">Monobactams</a></li><li><a href="bnf_int173-nitrofurantoin.htm" title="Nitrofurantoin">Nitrofurantoin</a></li><li id="_bnf_int785-nitroimidazoles"><a href="bnf_int785-nitroimidazoles.htm" title="Nitroimidazoles">Nitroimidazoles</a></li><li id="_bnf_int174-penicillins"><a href="bnf_int174-penicillins.htm" title="Penicillins">Penicillins</a></li><li id="_bnf_int189-polymyxins"><a href="bnf_int189-polymyxins.htm" title="Polymyxins">Polymyxins</a></li><li><a href="bnf_int192-pyrazinamide.htm" title="Pyrazinamide">Pyrazinamide</a></li><li id="_bnf_int193-quinolones"><a href="bnf_int193-quinolones.htm" title="Quinolones">Quinolones</a></li><li id="_bnf_int199-rifamycins"><a href="bnf_int199-rifamycins.htm" title="Rifamycins">Rifamycins</a></li><li id="_bnf_int203-sulfonamides"><a href="bnf_int203-sulfonamides.htm" title="Sulfonamides">Sulfonamides</a></li><li id="_bnf_int209-tetracyclines"><a href="bnf_int209-tetracyclines.htm" title="Tetracyclines">Tetracyclines</a></li><li><a href="bnf_int852-teicoplanin.htm" title="Teicoplanin">Teicoplanin</a></li><li><a href="bnf_int217-trimethoprim.htm" title="Trimethoprim">Trimethoprim</a></li><li><a href="bnf_int218-vancomycin.htm" title="Vancomycin">Vancomycin</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int125-propafenone.htm">Previous: Propafenone</a> | <a class="top" href="bnf_int127-antibacterials.htm#">Top</a> | <a accesskey="]" href="bnf_int1069-tigecycline.htm">Next: Tigecycline</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>